Brief: Eiger Biopharmaceuticals Announces Second Positive Interim Analysis And Continuation Of Dosing Of Peginterferon Lambda In Phase 3 Together Study Of Newly Diagnosed Covid-19 Patients
15/12/2021 13:47
Dec 15 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS ANNOUNCES SECOND POSITIVE INTERIM
ANALYSIS AND CONTINUATION OF DOSING OF PEGINTERFERON LAMBDA IN
PHASE 3 TOGETHER STUDY OF NEWLY DIAGNOSED COVID-19 PATIENTS
Source text for Eikon: ID:nPn8WSR4Da
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview